{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-274515","form_type":"8-K","ticker":"INO","cik":"0001055726","company_name":"INOVIO PHARMACEUTICALS, INC.","filed_at":"2023-11-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:28.058843+00:00","generated_at":"2026-06-08T06:01:41.440445+00:00","sec_items":["2.02","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"INOVIO gets FDA breakthrough therapy for INO-3107; BLA on accelerated path without Phase 3 trial","bullets":["FDA granted Breakthrough Therapy designation for INO-3107 to treat Recurrent Respiratory Papillomatosis (RRP).","FDA confirmed Phase 1/2 trial data can support BLA submission under accelerated approval; no Phase 3 required.","Cash, cash equivalents and short-term investments of $167.5M as of September 30, 2023.","INOVIO planning to submit BLA under accelerated approval; type B meeting requested for Q4 2023.","Commercialization strategy accelerated for potential earlier launch of INO-3107 if approved."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-274515","json":"https://secwatch.observer/filing/0001193125-23-274515.json","markdown":"https://secwatch.observer/filing/0001193125-23-274515.md","text":"https://secwatch.observer/filing/0001193125-23-274515.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1055726/000119312523274515/0001193125-23-274515-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1055726/000119312523274515/d295356d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T06:01:41.440445+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"333b465f413b8c31367ec0a2420b3d177d00d260","claim":"INOVIO PHARMACEUTICALS, INC. reported financial results for third quarter ended September 30, 2023.","evidence_excerpt":"On November 9, 2023, Inovio Pharmaceuticals, Inc. (the “ Company ”) issued a press release announcing its financial results for the quarter and nine months ended September 30, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1055726/000119312523274515/0001193125-23-274515-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"third quarter ended September 30, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}